AFP and Cirrhosis: To this end, we divided patients treated with TACE into subgroups according to their clinical characteristics (age ≤ 50 and >50; tumor size ≤ 5 and >5 cm; AFP > 300 ng/mL; BCLC stage A; cirrhosis; TNM stages I, II, and III).